4basebio PLC

LSE 4BB.L

4basebio PLC EBITDA Margin for the year ending December 31, 2023: -1,451.19%

4basebio PLC EBITDA Margin is -1,451.19% for the year ending December 31, 2023, a 28.10% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

4basebio PLC EBITDA Margin for the year ending December 31, 2022 was -2,018.28%, a -112.72% change year over year.
4basebio PLC EBITDA Margin for the year ending December 31, 2021 was -948.82%, a -1,166.92% change year over year.
4basebio PLC EBITDA Margin for the year ending December 31, 2020 was -74.89%, a -11.24% change year over year.
4basebio PLC EBITDA Margin for the year ending December 31, 2019 was -67.33%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

LSE: 4BB.L

4basebio PLC

CEO	Dr. Heikki Lanckriet Ph.D.
IPO Date	Feb. 17, 2021
Location	United Kingdom
Headquarters	25 Norman Way
Employees	101
Sector	Healthcare
Industries Biotechnology Hardware & Electronics Pharmaceuticals Plastics Vaccines

Description

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.

Key trends

Past 5 years